Genentech Ends $2 Billion Cancer Cell Therapy Deal With Adaptive Biotechnologies After $310 Million Paid Since 2018

Genentech has terminated its oncology collaboration with Adaptive Biotechnologies, a partnership initially established in 2018 to develop T cell receptor-based therapies for cancer. The deal was once valued at up to $2 billion, with Genentech having paid Adaptive $300 million upfront. However, the collaboration ended after Adaptive received a total payout of approximately $310 million. The termination marks the end of a multi-year effort to advance cell therapy in cancer treatment. This development comes amid other industry advancements, including N-Power Medicine launching a prospective external control arm platform to accelerate oncology drug development, āshibio expanding its clinical pipeline with a novel antibody for autosomal dominant osteopetrosis type 2, and Twist Bioscience introducing an oncology DNA comprehensive genomic profiling panel to enhance precision medicine.